We assessed whether the admission fasting plasma glucose (FPG) levels were associated with all-cause mortality and left ventricular (LV) function in older patients with acute myocardial infarction (AMI). A total of 1854 consecutive patients were categorized into 4 groups: hypoglycemia, euglycemia, mild hyperglycemia, and severe hyperglycemia. The primary outcomes were in-hospital/3-year mortality and LV function. There was a near-linear relationship between FPG and Killip class. However, no significant correlation was found between FPG levels and LV ejection fraction. Both FPG levels and Killip classes were all independent significant predictors of mortality. Compared with the euglycemia group, both the hypo- and hyperglycemia groups were associated with higher in-hospital and 3-year mortality. In older patients with AMI, the FPG values had differential influences on LV function and mortality. There was a U-shaped relationship between FPG and in-hospital/3-year mortality, and a near-linear relationship between increased admission glucose levels and higher Killip classification.
CapesSEHuntDMalmbergKGersteinHC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355(9206):773–778.
2.
WahabNNCowdenEAPearceNJ. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?J Am Coll Cardiol. 2002;40(10):1748–1754.
3.
StrandersIDiamantMvan GelderRE. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med. 2004;164(9):982–988.
4.
FooKCooperJDeanerA. A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart. 2003;89(5):512–516.
5.
KosiborodMRathoreSSInzucchiSE. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111(23):3078–3086.
6.
IwakuraKItoHIkushimaM. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41(1):1–7.
7.
IshiharaMKojimaSSakamotoT. Comparison of blood glucose values on admission for acute myocardial infarction in patients with versus without diabetes mellitus. Am J Cardiol. 2009;104(6):769–774.
8.
SuleimanMHammermanHBoulosM. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation. 2005;111(6):754–760.
9.
AronsonDHammermanHKapeliovichMR. Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function. Diabetes Care. 2007;30(4):960–966.
10.
PorterAAssaliARZahalkaA. Impaired fasting glucose and outcomes of ST-elevation acute coronary syndrome treated with primary percutaneous intervention among patients without previously known diabetes mellitus. Am Heart J. 2008;155(2):284–289.
11.
VergèsBZellerMDentanG. Impact of fasting glycemia on short term prognosis after acute myocardial infarction. J Clin Endocrinol Metab. 2007;92(6):2136–2140.
12.
WittelesRMTangWHJamaliAHChuJWReavenGMFowlerMB. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol. 2004;44(1):78–81.
13.
SuskinNMcKelvieRSBurnsRJ. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J. 2000;21(16):1368–1375.
14.
O’SullivanJJConroyRMRobinsonKHickeyNMulcahyR. In-hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction. Diabetes Care. 1991;14(8):758–760.
15.
ThomassenARMortensenPTNielsenTTFalstie-JensenNThygesenKHenningsenP. Altered plasma concentrations of glutamate, alanine and citrate in the early phase of acute myocardial infarction in man. Eur Heart J. 1986;7(9):773–778.
16.
OswaldGASmithCCBetteridgeDJYudkinJS. Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J (Clin Res Ed). 1986;293(6552):917–922.
17.
BellodiGManicardiVMalavasiV. Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol. 1989;64(14):885–888.
18.
IshiharaMInoueIKawagoeT. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J. 2003;146(4):674–678.
19.
ThygesenKAlpertJSWhiteHDJoint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28(20):2525–2538.
20.
ParakhKThombsBDBhatUFauerbachJABushDEZiegelsteinRC. Long-term significance of Killip class and left ventricular systolic dysfunction. Am J Med. 2008;121(11):1015–1018.
21.
KrumholzHMMurilloJEChenJ. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA. 1997;277(21):1683–1688.
22.
SvenssonAMMcGuireDKAbrahamssonPDellborgM. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26(13):1255–1261.
23.
KosiborodMInzucchiSEGoyalA. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA. 2009;301(15):1556–1564.
24.
GoyalAMehtaSRDíazR. Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation. 2009;120(24):2429–2437.
25.
MellbinLGMalmbergKWaldenströmAWedelHRydénLDIGAMI 2 investigators. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial. Heart. 2009;95(9):721–727.
26.
OliverMF. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med. 2002;112(4):305–311.
27.
ScognamiglioRNegutCDe KreutzenbergSVTiengoAAvogaroA. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation. 2005;112(2):179–184.
28.
GreselePGuglielminiGDe AngelisM. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol. 2003;41(6):1013–1020.
29.
AljadaAFriedmanJGhanimH. Glucose ingestion induces an increase in intranuclear nuclear factor kappa B, a fall in cellular inhibitor kappa B, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism. 2006;55(9):1177–1185.
30.
KawanoHMotoyamaTHirashimaO. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34(1):146–154.
31.
MohantyPHamoudaWGargRAljadaAGhanimHDandonaP. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab. 2000;85(8):2970–2973.
32.
GalassettiPDavisSN. Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond). 2000;99(5):351–362.
33.
HellerSR. Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome?Int J Clin Pract Suppl. 2002;129:27–32.
34.
MalmbergKRydénLWedelH. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26(7):650–661.
35.
CheungNWWongVWMcLeanM. The Hyperglycemia: intensive insulin infusion in infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29(4):765–770.
36.
The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–2515.
37.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
38.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
